The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up

Background Early prediction of lamivudine (LAM) response by individualized monitoring of serum HBV DNA like roadmap concept, and investigation of the outcome after LAM discontinuation in renal transplant recipients (RTRs) with chronic hepatitis B (CHB).